BioSpace News Archive

Wheeler Bio, Inc. today announced the appointment of Marc Helouin as Chief Quality and Regulatory Officer (CQRO).

Aurisco Pharmaceutical announced that its API and FDF plant in Yangzhou, China has successfully passed a cGMP inspection by the US Food and Drug Administration.

Everest Medicines (HKEX 1952.HK)'s partner Venatorx Pharmaceuticals announced that the U.S. Food and Drug Administration (FDA) has accepted the company’s New Drug Application (NDA) for cefepime-taniborbactam, an investigational beta-lactam/beta-lactamase inhibitor (BL/BLI) antibiotic for the potential treatment of adult patients with complicated urinary tract infections (cUTI), including pyelonephritis.

Enspire DBS Therapy, Inc., (Enspire) a clinical stage company developing an implantable neuromodulation therapy for post-stroke recovery, announced today the publication of the results of The EDEN trial (Electrical Stimulation of the Dentate Nucleus for Upper Extremity Hemiparesis Due to Ischemic Stroke), an early feasibility study led by Cleveland Clinic researchers, in Nature Medicine.

Biotricity Inc. today announced its financial results for the first quarter of fiscal 2024 year ended June 30, 2023.

Ashvattha Therapeutics (“Ashvattha”), a clinical-stage company developing a new class of nanomedicine therapeutics, today announced a poster presentation of preclinical data on ASH41020, its new ‘dendranib’ nanomedicine candidate, at the International Society of Neuroimmunology Congress (ISNI) being held August 21 – 24, 2023 in Québec City, Canada.

Ascendis Pharma A/S (Nasdaq: ASND) today announced it will report second quarter 2023 financial results and provide a business update on Tuesday, September 5, 2023, after the close of the U.S. financial markets.

Microbot Medical Inc. announces another step in its commitment to advance the commercialization processes of LIBERTY® with the signing of a manufacturing agreement with B.Y. Medimor Ltd.

Nanalysis Scientific Corp., a leader in portable NMR machines and MRI technology for industrial and research applications announces that on Thursday, August 24th, 2023, the Company will put out a press release and Chief Executive Officer Sean Krakiwsky and Chief Financial Officer Randall McRae will host a conference call at 5:00 P.M. Eastern Time to discuss the results for the quarter ending June 30, 2023.

Gilead Sciences, Inc. and Tentarix Biotherapeutics announced that the companies established three multi-year collaborations leveraging Tentarix’s proprietary Tentacles™ platform to discover and develop multi-functional, conditional protein therapeutics for oncology and inflammatory diseases.